

# Guidelines on Non-muscle-invasive **Bladder Cancer** (TaT1 and CIS)

M. Babjuk, W. Oosterlinck, R. Sylvester,  
E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt

# TABLE OF CONTENTS

# PAGE

1.	BACKGROUND	4
1.1	Publication history	4
1.2	Methodology	4
2.	EPIDEMIOLOGY	5
3.	RISK FACTORS	5
4.	CLASSIFICATION	6
4.1	Tumour, Node, Metastasis Classification (TNM)	6
4.2	Histological grading of non-muscle-invasive bladder urothelial carcinomas	6
4.3	Controversial definition of non-muscle-invasive (“superficial”) tumours	8
4.4	Inter- and intra-observer variability in staging and grading	8
4.5	Specific character of carcinoma <i>in situ</i> (CIS) and its clinical classification	8
5.	DIAGNOSIS	8
5.1	Symptoms	8
5.2	Physical examination	8
5.3	Imaging	8
5.3.1	Intravenous urography and computed tomography	8
5.3.2	Ultrasonography	9
5.4	Urinary cytology	9
5.5	Urinary molecular marker tests	9
5.6	Practical application of urinary cytology and markers	10
5.7	Cystoscopy	11
5.8	Transurethral resection (TUR) of TaT1 bladder tumours	11
5.9	Bladder and prostatic urethral biopsies	11
5.10	Photodynamic diagnosis (fluorescence cystoscopy)	12
5.11	Second resection	12
5.12	Pathological report	13
5.13	Recommendations for primary assessment of non-muscle-invasive bladder tumours	13
6.	PREDICTING RECURRENCE AND PROGRESSION	13
6.1	TaT1 tumours	13
6.2	Carcinoma <i>in situ</i>	15
7.	ADJUVANT TREATMENT	16
7.1	Intravesical chemotherapy	16
7.1.1	One, immediate, postoperative intravesical instillation of chemotherapy	16
7.1.2	Additional adjuvant intravesical chemotherapy instillations	17
7.1.3	Optimising intravesical chemotherapy	17
7.2	Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy	17
7.2.1	Efficacy of BCG	17
7.2.2	Optimal BCG schedule	18
7.2.3	Optimal dose of BCG	18
7.2.4	BCG toxicity	18
7.2.5	Indications for BCG	18
7.3	Specific aspects of treatment of carcinoma <i>in situ</i>	18
7.3.1	Treatment strategy	18
7.3.2	Cohort studies	19
7.3.3	Prospective randomised trials	19
7.3.4	Treatment of extravesical CIS	19
7.4	Treatment of failure of intravesical therapy	19
7.4.1	Failure of intravesical chemotherapy	19
7.4.2	Failure of intravesical BCG immunotherapy	19
7.5	Recommendations for adjuvant therapy in TaT1 tumours and for therapy of CIS	20

8.	CYSTECTOMY FOR NON-MUSCLE-INVASIVE BLADDER CANCER	21
9.	FOLLOW-UP OF PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER TUMOURS	21
9.1	Recommendations for follow-up in patients after TUR of non-muscle-invasive bladder cancer	22
10.	REFERENCES	22
11.	ABBREVIATIONS USED IN THE TEXT	35

# 1. BACKGROUND

## 1.1 Publication history

The first European Association of Urology (EAU) Guidelines on Bladder Cancer were published in 2002 (1). It was later decided to develop separate guidelines for different categories of urothelial tumours:

- TaT1 papillary tumours (non-muscle-invasive bladder cancer);
- Carcinoma *in situ* (CIS);
- Muscle-invasive bladder tumours;
- Upper urinary tract tumours.

Separate guidelines have been published in European Urology for TaT1, CIS, and upper urinary tract tumours (2-4). For logistical reasons, the guidelines group on non-muscle-invasive bladder cancer decided to integrate the guidelines of TaT1 tumours and CIS in one issue. This overview represents the updated EAU guidelines for non-muscle-invasive bladder cancer (CIS, Ta, T1).

## 1.2 Methodology

The systematic literature search for each section of the non-muscle-invasive bladder cancer guidelines was performed by the panel members. For identification of original and review articles, the Medline, Web of Science, and Embase databases were used. For the current upgrade, all articles published between 2008 and 2010 on TaT1 tumours and between 2004 and 2010 on CIS were considered. Focus of the searches was identification of all level 1 scientific papers (systematic reviews and meta-analyses of randomised controlled trials [RCTs]) in accordance with EAU methodology. Panel members rated papers following a classification system modified from the Oxford Centre for Evidence-based Medicine Levels of Evidence (LE) (5). Additionally, recommendations have been graded to provide transparency between the underlying evidence and a recommendation given.

**Table 1: Level of evidence\***

Level	Type of evidence
1a	Evidence obtained from meta-analysis of randomised trials
1b	Evidence obtained from at least one randomised trial
2a	Evidence obtained from one well-designed controlled study without randomisation
2b	Evidence obtained from at least one other type of well-designed quasi-experimental study
3	Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports
4	Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities

\*Modified from Sackett *et al.* (5).

It should be noted that when recommendations are graded, the link between the level of evidence and grade of recommendation (GR) is not directly linear. Availability of RCTs may not necessarily translate into a grade A recommendation where there are methodological limitations or disparity in published results.

Alternatively, absence of high level of evidence does not necessarily preclude a grade A recommendation, if there is overwhelming clinical experience and consensus. In addition, there may be exceptional situations where corroborating studies cannot be performed, perhaps for ethical or other reasons and in this case unequivocal recommendations are considered helpful for the reader. The quality of the underlying scientific evidence - although a very important factor - has to be balanced against benefits and burdens, values and preferences, and costs when a grade is assigned (6-8).

The EAU Guidelines Office do not perform cost assessments, nor can they address local/national preferences in a systematic fashion. But whenever this data is available, the expert panel will include the information.

**Table 2: Grade of recommendation\***

<b>Grade</b>	<b>Nature of recommendations</b>
A	Based on clinical studies of good quality and consistency that addressed the specific recommendations, including at least one randomised trial
B	Based on well-conducted clinical studies, but without randomised clinical trials
C	Made despite the absence of directly applicable clinical studies of good quality

\*Modified from Sackett et al. (5).

## **2. EPIDEMIOLOGY**

Bladder carcinoma is the most common malignancy of the urinary tract. The worldwide age standardised incidence rate (ASR) is 10.1 per 100,000 for males and 2.5 per 100,000 for females (9). In Europe, the highest incidence has been reported in the Western (23.6 in males and 5.4 in females) and Southern (27.1 in males and 4.1 in females) regions, followed by Northern Europe (16.9 in males and 4.9 in females). The lowest incidence is observed in Eastern European countries (14.7 in males and 2.2 in females) (10).

The global world mortality rate among males is 4 per 100,000 versus 1.1 per 100,000 among females. The ASR (per 100,000) only varies between 5.6 in developed countries and 3.1 in developing countries for males. For females the ASR varies between 1.4 in developed countries and 0.9 in less developed areas (9). In Europe, mortality rates show a substantial decline over the last decade of about 16% in men and about 12% in women (11).

Approximately 75-85% of patients with bladder cancer present with a disease that is confined to the mucosa (stage Ta, CIS) or submucosa (stage T1). These categories are grouped as non-muscle-invasive bladder tumours.

## **3. RISK FACTORS**

Many of the aetiological factors for the development of bladder tumours are known and urologists should be aware of the types of occupational exposure that might be related to urothelial carcinogens (12-14). Aromatic amines were the first to be recognised. At-risk groups include workers in the following industries: printing, iron and aluminium processing, industrial painting, gas and tar manufacturing (LE: 3).

Another prominent risk factor is cigarette smoking, which triples the risk of developing bladder cancer (15-17) (LE: 2a). Smoking leads to a higher mortality rate from bladder cancer during long-term follow-up, even though, in a multivariate analysis, the prognostic effect of smoking was weaker than that of other factors, such as stage, grade, size, and multifocality of the tumour (18).

## 4. CLASSIFICATION

### 4.1 Tumour, Node, Metastasis Classification (TNM)

The 2002 TNM classification approved by the Union International Contre le Cancer (UICC) has been widely accepted. This version was updated in 2009, but it has no changes for bladder tumours (Table 3) (19).

**Table 3: 2009 TNM classification of urinary bladder cancer**

<b>T - Primary tumour</b>	
TX	Primary tumour cannot be assessed
T0	No evidence of primary tumour
Ta	Non-invasive papillary carcinoma
Tis	Carcinoma <i>in situ</i> : 'flat tumour'
T1	Tumour invades subepithelial connective tissue
T2	Tumour invades muscle
T2a	Tumour invades superficial muscle (inner half)
T2b	Tumour invades deep muscle (outer half)
T3	Tumour invades perivesical tissue:
T3a	Microscopically
T3b	Macroscopically (extravesical mass)
T4	Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall
T4a	Tumour invades prostate, uterus or vagina
T4b	Tumour invades pelvic wall or abdominal wall
<b>N - Lymph nodes</b>	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in a single lymph node in the true pelvis (hypogastric, obturator, external iliac, or presacral)
N2	Metastasis in multiple lymph nodes in the true pelvis (hypogastric, obturator, external iliac, or presacral)
N3	Metastasis in common iliac lymph node(s)
<b>M - Distant metastasis</b>	
MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis

### 4.2 Histological grading of non-muscle-invasive bladder urothelial carcinomas

In 1998, a new classification of non-invasive urothelial tumours was proposed by the World Health Organization (WHO) and the International Society of Urological Pathology (ISUP) (1998 WHO/ISUP classification) and published by the WHO in 2004 (20,21) (Table 4). Its major contribution is a detailed histological description of the various grades, which uses specific cytological and architectural criteria. A website ([www.pathology.jhu.edu/bladder](http://www.pathology.jhu.edu/bladder)) that illustrates examples of various grades has been developed to improve accuracy further in using the system.

**Table 4: WHO grading in 1973 and in 2004 (20,21)**

<p><b>1973 WHO grading</b></p> <p>Urothelial papilloma</p> <p>Grade 1: well differentiated</p> <p>Grade 2: moderately differentiated</p> <p>Grade 3: poorly differentiated</p>
<p><b>2004 WHO grading</b></p> <p>Flat lesions</p> <p>Hyperplasia (flat lesion without atypia or papillary aspects)</p> <p>Reactive atypia (flat lesion with atypia)</p> <p>Atypia of unknown significance</p> <p>Urothelial dysplasia</p> <p>Urothelial CIS</p> <p>Papillary lesions</p> <p>Urothelial papilloma (completely benign lesion)</p> <p>Papillary urothelial neoplasm of low malignant potential (PUNLMP)</p> <p>Low-grade papillary urothelial carcinoma</p> <p>High-grade papillary urothelial carcinoma</p>


The 2004 WHO classification of the flat lesions includes urothelial hyperplasia, reactive urothelial atypia, atypia of unknown significance, dysplasia and CIS. Among non-invasive papillary urothelial lesions, the 2004 WHO grading differentiates between PUNLMP and low-grade and high-grade urothelial carcinomas.

Papillary urothelial neoplasm of low malignant potentials are defined as lesions that do not have cytological features of malignancy but show normal urothelial cells in a papillary configuration. Although they have a negligible risk for progression, they are not completely benign and still have a tendency to recur. The intermediate grade (grade 2), which was the subject of controversy in the 1973 WHO classification, has been eliminated (22,23) (Figure 1).

It was shown that the 2004 WHO classification has a better reproducibility than the WHO 1973 classification (24).

The prognostic value of both grading systems (WHO 1973 and 2004) has been confirmed. Attempts to demonstrate better prognostic value of one system over another, however, have yielded controversial results (22-25). The majority of clinical trials published to date on TaT1 bladder tumours have been performed using the 1973 WHO classification, and therefore, the following guidelines are based on this scheme. Until the prognostic role of WHO 2004 is validated by more prospective trials, both classifications can be used.

**Figure 1: Stratification of tumours according to grade in the WHO 1973 and 2004 classifications (26)\***



**Histologic Spectrum of transitional cell carcinoma (TCC)**

*Fig. 1 - Comparison of the 1973 and 2004 WHO grading system. The 1973 WHO grade 1 carcinomas are reassigned, some to the PUNLMP category, and some to the low-grade carcinoma category. Similarly, 1973 WHO grade 2 carcinomas are reassigned, some to the low-grade carcinoma category, and others to the high-grade carcinoma category. All 1973 WHO tumours are assigned to the high-grade carcinoma category. WHO = World Health Organization; PUNLMP = papillary urothelial neoplasm of low malignant potential.*

*\*Figure reproduced with permission from MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007 Apr;51(4):889-98. Copyright 2007 Elsevier.*

### 4.3 Controversial definition of non-muscle-invasive (“superficial”) tumours

The diagnosis of non-muscle-invasive bladder cancer requires consideration of all transurethral resection (TUR) samples.

A papillary tumour confined to the mucosa is classified as stage Ta according to the TNM system. Tumours that have invaded the lamina propria are classified as stage T1. Ta and T1 tumours can be removed by TUR, and therefore, they are grouped under the heading of non-muscle-invasive bladder cancer for therapeutic purposes. Also included under this heading are flat, high-grade tumours that are confined to the mucosa, and classified as CIS (Tis). However, molecular biology techniques and clinical experience have demonstrated the highly malignant, invasive potential of CIS and T1 lesions. Therefore, the terms non-muscle-invasive and superficial bladder cancer are suboptimal descriptions.

Some promising prognostic factors that are based on pathological examination of resected tissue have been presented:

- In patients with T1 tumours, the depth of invasion into the lamina propria is considered. The depth of invasion is evaluated in relation to the muscularis mucosae layer. T1 tumours are substaged into T1a (tumours that extend into the lamina propria but above the level of the muscularis mucosae) and T1b (tumours that infiltrate into or below the level of the muscularis mucosae). The prognostic value of T1 substaging has been demonstrated by some retrospective cohort studies (27-29) (LE: 3).
- The presence of lymphovascular invasion has been recognised as an unfavourable prognostic factor in T1 tumours (29,30) (LE: 3).
- Detection of the micropapillary variant of urothelial carcinoma represents a poor prognostic factor (31) (LE: 3).

### 4.4 Inter- and intra-observer variability in staging and grading

Despite well-defined criteria for the diagnosis of urothelial carcinoma, there is significant variability among pathologists for diagnosis of CIS, for which agreement is achieved in only 70-78% of cases (32,33). There is also important inter-observer variability in classification of stage T1 versus Ta tumours, and grading tumours with general conformity between 50 and 60% (24,32-36). The inter-observer variability is less with the 2004 WHO classification compared to the 1973 classification (23,24). However, a review of slides is recommended particularly in T1, CIS and high-grade lesions.

### 4.5 Specific character of CIS and its clinical classification

Carcinoma *in situ* is a flat, high-grade, non-invasive urothelial carcinoma. The term CIS might suggest that it is a precursor of cancer. Although it might be a precursor of invasive bladder cancer, the histological and cytological aspects of CIS make this an overtly malignant entity in itself.

Macroscopically, CIS can be missed at cystoscopy or be considered as an inflammatory lesion if it is not biopsied. It is often multifocal and can occur in the upper urinary tract and in the prostatic ducts and urethra (37).

Carcinoma *in situ* is classified into one of three different clinical types (38):

- Primary: isolated CIS with no previous or concurrent exophytic tumours;
- Secondary: CIS detected during the follow-up of patients with a previous tumour;
- Concurrent: CIS in the presence of exophytic tumours.

## 5. DIAGNOSIS

### 5.1 Symptoms

Haematuria is the most common finding in non-muscle-invasive bladder cancer. Ta/T1 tumours do not cause bladder pain and rarely present with lower urinary tract symptoms. In patients who do complain of these symptoms, CIS might be suspected.

### 5.2 Physical examination

Physical examination does not reveal non-muscle-invasive bladder cancer.

### 5.3 Imaging

#### 5.3.1 Intravenous urography and computed tomography

Intravenous urography (IVU) is used to detect filling defects in the calyces, renal pelvis and ureters, and



hydronephrosis, which can indicate the presence of a ureteral tumour. Large exophytic tumours may be seen as filling defects in the bladder. The necessity to perform routine IVU once a bladder tumour has been detected is now questioned because of the low incidence of significant findings obtained with this method (39-41) (LE: 3). The incidence of upper urinary tract tumours is low (1.8%), but increases to 7.5% in tumours located in the trigone (40). The risk of tumour recurrence in the upper urinary tract during follow-up increases in multiple and high-risk tumours (42).

In many centres, computed tomography (CT) urography is used as an alternative to conventional IVU (43). Especially in muscle-invasive tumours of the bladder and in upper tract tumours, CT urography gives more information than IVU does (including status of lymph nodes and neighbouring organs) (LE: 4). However, CT urography has the disadvantage of higher radiation exposure compared to IVU.

### 5.3.2 **Ultrasonography**

Ultrasonography (US) has been used with increasing frequency as the initial tool to assess the urinary tract. This is not only because it avoids the use of contrast agents, but also because sensitive transducers have improved imaging of the upper urinary tract and bladder.

Transabdominal US permits characterisation of renal masses, detection of hydronephrosis and visualisation of intraluminal masses in the bladder. It can be as accurate as IVU for diagnosis of upper urinary tract obstruction (39) (LE: 3). The US is thus a useful tool for investigation in patients with haematuria to detect obstruction, it cannot however exclude the presence of upper tract tumours. Imaging methods (IVU, CT urography or US) have no role in the diagnosis of CIS.

## 5.4 **Urinary cytology**

Examination of voided urine or bladder-washing specimens for exfoliated cancer cells has high sensitivity in high-grade tumours but low sensitivity in low-grade tumours (LE: 2b). Due to a loss of cohesion of cells in the epithelial lining of the bladder in CIS, there is a larger number of floating cells in the urine, as well as a high degree of anaplasia. Thanks to these conditions is the sensitivity of cytology in CIS detection > 90%. Cytology is thus useful when a high-grade malignancy or CIS is present. However, urinary cytology often is negative in the presence of low-grade cancer. Positive voided urinary cytology can indicate a urothelial tumour anywhere in the urinary tract, from the calyx to the ureters, bladder and proximal urethra.

Cytological interpretation is user-dependent (44). Evaluation can be hampered by low cellular yield, urinary tract infections, stones or intravesical instillations. In experienced hands however, the specificity exceeds 90% (45) (LE: 2b). Cytology should be performed on fresh urine with adequate fixation. Morning urine is not suitable because of the frequent presence of cytolysis.

## 5.5 **Urinary molecular marker tests**

Extensive laboratory research has developed numerous urinary tests for diagnosis of bladder cancer based on detection of soluble or cell-associated markers (45-51).

Numerous reviews of urinary markers have appeared in recent years (45-59). A few of the markers have come into clinical application but none has been accepted as a standard diagnostic procedure in routine urology or in guidelines until now. Three tests are particularly promising: nuclear matrix protein 22 (NMP22), UroVysion®, and ImmunoCyt (49,50,60-64).

The following conclusions can be drawn about the existing tests. The bladder tumour antigen (BTA) test has a very limited role because of its high false-positive rate and low sensitivity for low-grade tumours (65,66). NMP22 similarly suffers from a high false-positive rate but has higher sensitivity than urinary cytology. With careful selection of patients, the specificity of NMP22 can be improved, and because of its high negative predictive volume (NPV), it can potentially be used during follow-up to delay cystoscopy control (60,62,67-69). ImmunoCyt has the highest sensitivity for detection of low-grade tumours and is less affected by other urological diseases. However, with a 60% detection rate for low-grade tumours, the test remains largely inadequate to replace cystoscopy (64,70). UroVysion® adds little to the surveillance of low-grade tumours. However, it can replace cytology for high-grade tumours when experience with urinary cytology is lacking or when its result is inconclusive. Some false-positive results arise because UroVysion® can detect occult disease and thus identify those patients who are more likely to experience recurrence. It might also be useful to predict response to intravesical therapy (63,71,72). Microsatellite analysis is the most promising of the methods listed in Table 5. It can predict recurrence of low-grade tumours in up to 80% of cases, but it still lacks sensitivity (73-75).

The sensitivity of tests can be improved by their combination, as suggested by the International Consensus Panel on Bladder Tumour Markers (45).

Although it is hoped that these tests can soon make the transition from the laboratory to the clinic, it is essential to evaluate their costs to determine whether they can provide a low-cost and reliable alternative to current cystoscopy methods (76).

Table 5 gives an overview of how far the available urinary markers correspond to some of these criteria (52).

**Table 5: Summary of main urinary markers**

Markers	Overall sensitivity (%)	Overall specificity (%)	Sensitivity for high-grade tumours (%)	Point-of-care test	Interference by BCG instillations and other bladder conditions	Comments
UroVysion®	30-72	63-95	66-70	No	No	Expensive and laborious
Microsatellite analysis	58	73	90	No	No	Expensive and laborious
Gene microarray	80-90	62-65	80	No	No	Expensive and laborious
Immunocyt/uCyt +™	76-85	63-75	67-92	No	Yes	Good sensitivity in low-grade tumours, affected by BCG
Nuclear matrix protein 22	49-68	85-87.5	75-83	Yes	Yes	Low sensitivity, affected by benign conditions
BTA stat	57-83	68-85	61.5	Yes	Yes	Low sensitivity, affected by benign conditions and BCG
BTA TRAK	53-91	28-83	77	No	Yes	Low sensitivity, affected by benign conditions and BCG
Cytokeratins	12-85	75-97	33-82	No	Yes	Low sensitivity, affected by benign conditions and BCG
Survivin	53-90	88-100	50	No	No	Low sensitivity, expensive and laborious

BCG = *Bacillus Calmette-Guérin*; BTA = bladder tumour antigen.

## 5.6 Practical application of urinary cytology and markers

There are specified general requirements for good markers for bladder cancer (45):

- The test must be as simple as possible technically (preferably a point-of-care test, with readily available results, easy to perform, with a short learning curve);
- Low cost;
- Reliable and reproducible results;
- High diagnostic accuracy (high sensitivity and specificity);
- For individual patient populations and clinical situations, the test should have a high positive predictive value to avoid unnecessary workup because of false-positive results, and high NPV to avoid the risk of failing to detect tumours. These parameters vary between populations with different incidences of bladder cancer and cannot be used for general comparison of methods;
- For clinical settings, it is of utmost importance to detect reliably all high-grade tumours before they escape curative treatment.

The following objectives of application of urinary cytology or molecular tests must be considered:

- *Screening of the population at risk of bladder cancer.*  
The application of haematuria dipstick, NMP22 or UroVysion® in bladder cancer screening in high-risk

populations has been reported (60,61). However, concerns about feasibility and cost-effectiveness mean that routine application of screening has not yet been established.

- *Exploration of patients after haematuria or other symptoms that are suggestive of bladder cancer.* It is generally accepted that none of the tests can replace cystoscopy. However, urinary cytology or markers can be used as adjunct to cystoscopy to detect invisible tumours, particularly CIS. In this setting, the method should have high sensitivity and specificity for high-grade tumours. Urinary cytology is highly specific and sensitive in this regard. Most commercially available urinary markers are even slightly more sensitive than cytology, the problem is however their lack of specificity.
- *Facilitate surveillance of non-muscle-invasive bladder cancer to reduce the number of cystoscopies (48,52,62,65).*  
To reduce the number of cystoscopies, urinary markers should be able to detect recurrence before the tumours are large and numerous. The limitation of urinary cytology is its low sensitivity for low grade recurrences. Several urinary markers are better but still do not detect half of the low-grade tumours that are detected by cystoscopy. Among the commercially available tests, the best performance for detecting recurrence of low-grade tumours is by immunocytology. Large prospective studies on recurrence of low-grade tumours are still lacking, thus, urinary markers cannot safely replace cystoscopy in this setting.

## 5.7 Cystoscopy

The diagnosis of bladder cancer ultimately depends on cystoscopic examination of the bladder and histological evaluation of the resected tissue. The diagnosis of CIS is made by a combination of cystoscopy, urine cytology, and histological evaluation of multiple bladder biopsies (77).

Cystoscopy is initially performed in the office, using flexible instruments. If a bladder tumour has been visualised in earlier imaging studies, diagnostic cystoscopy can be omitted because the patient will undergo TUR.

A careful description of the findings is necessary. It should include the site, size, number, and appearance (papillary or solid) of the tumours, as well as a description of mucosal abnormalities. Use of a bladder diagram is recommended.

## 5.8 Transurethral resection (TUR) of TaT1 bladder tumours

The goal of the TUR in TaT1 bladder tumours is to make the correct diagnosis and remove all visible lesions.

The strategy of resection depends on the size of the lesion. Small tumours (< 1 cm) can be resected *en bloc*, the specimen contains the complete tumour plus a part of the underlying bladder wall. Some experts believe that deep resection is not necessary in small, apparently low-grade lesions with a previous history of TaG1 tumour. Larger tumours should be resected separately in fractions, which include the exophytic part of the tumour, the underlying bladder wall with the detrusor muscle, and the edges of the resection area. The specimens from different fractions must be referred to the pathologist in separate containers to enable him/her to make a correct diagnosis. Cauterisation should be avoided as much as possible during TUR to prevent tissue destruction.

Complete and correct TUR is essential to achieve a good prognosis (78). It has been confirmed that absence of detrusor muscle in the specimen is associated with a significantly higher risk of residual disease and early recurrence (79) (LE: 2).

## 5.9 Bladder and prostatic urethral biopsies

Carcinoma *in situ* can present as a velvet-like, reddish area that is indistinguishable from inflammation, or it might not be visible at all. It can be present as an isolated lesion without exophytic tumour, or it can accompany TaT1 tumours.

When abnormal areas of urothelium are seen, it is advised to take 'cold cup' biopsies or biopsies with a resection loop. Biopsies from normal-looking mucosa, so-called random biopsies (R-biopsies), should be performed in patients with positive urinary cytology and absence of visible tumour in the bladder. It is recommended to take R-biopsies from the trigone, bladder dome and from right, left, anterior and posterior bladder walls.

In patients with TaT1 tumours, R-biopsies are not routinely recommended. The likelihood of detecting CIS, especially in low-risk tumours, is extremely low (< 2%) (80) (LE: 2a). Cold cup biopsies from normal-looking mucosa should be performed when cytology is positive or when exophytic tumour has a non-papillary appearance. Material obtained by random or directed biopsies must be sent for pathological assessment in separate containers. In CIS, the coherence and adherence of epithelial cells is decreased, and this feature often

results in denuded biopsies when taken by cold cup or a resection loop (81).

Involvement of the prostatic urethra and ducts in male patients with non-muscle-invasive bladder cancer has been reported. Although the exact risk of prostatic urethra or ducts involvement is not known, it seems to be higher if the tumour is located on the trigone or bladder neck, in the presence of bladder CIS and multiple tumours (82,83) (LE: 3). In these cases and when cytology is positive, with no evidence of tumour in the bladder, or when abnormalities of prostatic urethra are visible, biopsies of the prostatic urethra are recommended. The biopsy is taken from abnormal areas and from the precollicular area (between 5 and 7 o'clock position) using a resection loop.

### **5.10 Photodynamic diagnosis (fluorescence cystoscopy)**

As a standard procedure, cystoscopy and TUR are performed using white light. However, the use of white light can lead to missing lesions that are present but not visible. Photodynamic diagnosis (PDD) is performed using violet light after intravesical instillation of 5-aminolaevulinic acid (ALA) or hexaminolaevulinic acid (HAL). It has been confirmed that fluorescence-guided biopsy and resection are more sensitive than conventional procedures for detection of malignant tumours, particularly for CIS (84-86) (LE: 2a). The additional detection rate with PDD was 20% for all tumours and 23% for CIS in a cumulative analysis of prospective trials (87). However, false-positivity can be induced by inflammation or recent TUR, and during the first 3 months after BCG instillation (88).

The benefit of ALA fluorescence-guided TUR for recurrence-free survival has been demonstrated in several small, randomised clinical trials (89-91). Cumulative analysis of three trials has shown that the recurrence-free survival was 15.8-27% higher at 12 months and 12-15% higher at 24 months in the fluorescence-guided TUR groups compared to the white light cystoscopy alone groups (87) (LE: 2) However, a large Swedish study could not detect any advantage in using ALA fluorescence-guided TUR routinely in all patients with non-muscle-invasive bladder cancer (92). A recent large, multicentre, prospective randomised trial that compared HAL fluorescence-guided TUR with standard TUR reported an absolute reduction of no more than 9% in the recurrence rate within 9 months in the HAL arm (93) (LE: 1b).

The value of fluorescence cystoscopy for improvement of the outcome in relation to progression rate or survival remains to be demonstrated.

Photodynamic diagnosis is most useful for detection of CIS, and therefore it should be restricted to those patients who are suspected of harbouring a high-grade tumour, e.g. for biopsy guidance in patients with positive cytology or with a history of high-grade tumour. Because of conflicting data on recurrence rate this panel restricts the indication for PDD more than experts in a recently published review (94).

The additional costs of the equipment and instillation for PDD should be taken into account.

### **5.11 Second resection**

The significant risk of residual tumour after initial TUR of TaT1 lesions has been demonstrated (78,95) (LE: 2a). Persistent disease after resection of T1 tumours has been observed in 33-53% of patients (95-100).

Moreover, the tumour is often under-staged by initial resection. The likelihood that a T1 tumour has been under-staged and muscle-invasive disease is detected by second resection ranges from 4 to 25%. This risk has increased up to 50% in some cystectomy series, although these studies have only enrolled selected patients (96,101,102) (LE: 2a). Treatment of a TaT1 high-grade tumour and a T2 tumour is completely different; therefore, correct staging is important.

A second TUR should be considered when the initial resection is incomplete, for example, when multiple and/or large tumours are present, or when the pathologist has reported that the specimen contains no muscle tissue (TaG1 excluded). Furthermore, a second TUR should be performed when a high-grade or T1 tumour has been detected at initial TUR (103). It has been demonstrated that a second TUR can increase the recurrence-free survival (98,99,104) (LE: 2a). There is no consensus about the strategy and timing of second TUR. Most authors recommend resection at 2-6 weeks after initial TUR. The procedure should include resection of the primary tumour site.

### **5.12 Pathological report**

Pathological investigation of the specimen obtained by TUR and biopsies is an essential step in the diagnosis of bladder cancer. The pathological report should specify the grade of the lesion(s) and the depth of tumour invasion into the bladder wall, and should give information about whether the lamina propria and sufficient muscle are present in the specimen (104).

Essential for correct pathological assessment is the high quality of resected tissue. The presence of sufficient muscle is necessary for correct assignment of T-category. Close cooperation between urologists and pathologists is recommended.

### 5.13 Recommendations for primary assessment of non-muscle-invasive bladder tumours

	GR
The renal and bladder US may be used during initial work-up in patients with haematuria.	C
At the time of initial diagnosis of bladder cancer CT urography or IVU should be performed only in selected cases (e.g. tumours located in the trigone).	B
Cystoscopy is recommended in all patients with symptoms suggestive of bladder cancer. It cannot be replaced by cytology nor by any other non-invasive test.	A
Cystoscopy should describe all macroscopic features of the tumour (site, size, number and appearance) and mucosal abnormalities. A bladder diagram is recommended.	C
Voided urine cytology or urinary markers are advocated to predict high grade tumour before TUR.	C
It is recommended to perform TUR in one piece for small papillary tumours (< 1 cm), including part from the underlying bladder wall.	B
It is recommended to perform TUR in fractions (including muscle tissue) for tumours > 1 cm in diameter.	B
It is recommended to take biopsies from abnormal-looking urothelium. Biopsies from normal-looking mucosa (trigone, bladder dome and from right, left, anterior and posterior bladder walls) are recommended only when cytology is positive or when exophytic tumour has a non-papillary appearance.	C
Biopsy of the prostatic urethra is recommended for cases of bladder neck tumour, when bladder CIS is present or suspected, when there is positive cytology without evidence of tumour in the bladder, or when abnormalities of the prostatic urethra are visible. If biopsy is not performed during the initial procedure, it should be completed at the time of the second resection. The biopsy should be taken from the precollicular area between 5 and 7 o'clock using a resection loop.	C
If equipment is available, fluorescence-guided (PDD) biopsy should be performed when bladder CIS is suspected (e.g. positive cytology, recurrent tumour with previous history of a high-grade lesion).	B
A second TUR should be performed at 2-6 weeks after initial resection when the latter is incomplete (in large and multiple tumours, no muscle in the specimen), or when an exophytic high-grade and/or T1 tumour is detected.	A
The pathological report should specify the grade, depth of tumour invasion, and whether the lamina propria and sufficient muscle are present in the specimen.	A

*CIS = carcinoma in situ; CT = computed tomography; IVU = intravenous urography; PDD = photodynamic diagnosis; TUR = transurethral resection; US = ultrasound.*

## 6. PREDICTING RECURRENCE AND PROGRESSION

### 6.1 TaT1 tumours

The classic way to categorise patients with TaT1 tumours is to divide them into risk groups based on prognostic factors derived from multivariate analyses. Using such a technique, it has been proposed to divide patients into low-risk, intermediate-risk and high-risk groups (105). When using these risk groups, however, no distinction is usually drawn between the risk of recurrence and progression. Although prognostic factors indicate a high risk for recurrence, the risk of progression might still be low, and other tumours might have a high risk of recurrence and progression.

In order to predict separately the short-term and long-term risks of recurrence and progression in individual patients, the European Organization for Research and Treatment of Cancer (EORTC) Genitourinary (GU) group has developed a scoring system and risk tables (106). The basis for these tables is the EORTC database, which provides individual patient data for 2,596 patients diagnosed with TaT1 tumours, who were randomised in seven EORTC-GU group trials. Patients with CIS alone are not included. Seventy-eight percent of patients have received intravesical treatment, mostly chemotherapy. However, they have not undergone a second TUR or received maintenance BCG. The scoring system is based on the six most significant clinical and pathological factors:

- number of tumours;
- tumour size;
- prior recurrence rate;
- T-category;
- presence of concurrent CIS;
- tumour grade.

Table 6 illustrates the weights applied to various factors for calculating the total scores for recurrence and progression. Table 7 shows the total scores stratified, as in the original article (106), into four categories that reflect various probabilities of recurrence and progression at 1 and 5 years. By combination of two of the four categories for recurrence and progression, the EAU working group suggests the use of a three-tier system that defines low-, intermediate- and high-risk groups for recurrence and progression, as shown in the rightmost column in Table 7.

**Table 6: Weighting used to calculate recurrence and progression scores**

Factor	Recurrence	Progression
Number of tumours		
Single	0	0
2-7	3	3
≥ 8	6	3
Tumour diameter		
< 3 cm	0	0
≥ 3 cm	3	3
Prior recurrence rate		
Primary	0	0
≤ 1 recurrence/year	2	2
> 1 recurrence/year	4	2
Category		
Ta	0	0
T1	1	4
Concurrent CIS		
No	0	0
Yes	1	6
Grade (WHO 1973)		
G1	0	0
G2	1	0
G3	2	5
Total score	0-17	0-23

CIS = carcinoma in situ; WHO = World Health Organization.

**Table 7: Probability of recurrence and progression according to total score**

Recurrence score	Probability of recurrence at 1 year		Probability of recurrence at 5 years		Recurrence risk group
	%	(95% CI)	%	(95% CI)	
0	15	(10-19)	31	(24-37)	Low risk
1-4	24	(21-26)	46	(42-49)	Intermediate risk
5-9	38	(35-41)	62	(58-65)	
10-17	61	(55-67)	78	(73-84)	High risk

Progression score	Probability of progression at 1 year		Probability of progression at 5 years		Progression risk group
	%	(95% CI)	%	(95% CI)	
0	0.2	(0-0.7)	0.8	(0-1.7)	Low risk
2-6	1	(0.4-1.6)	6	(5-8)	Intermediate risk
7-13	5	(4-7)	17	(14-20)	High risk
14-23	17	(10-24)	45	(35-55)	

Note: Electronic calculators for Tables 6 and 7 are available at <http://www.eortc.be/tools/bladdercalculator/>.

The scoring model for BCG-treated patients that predicts the short- and long-term risks of recurrence and progression has recently been presented by the Club Urológico Español de Tratamiento Oncológico (CUETO) (Spanish Urological Oncology Group). It is based on analysis of 1,062 patients from four CUETO trials that compared different intravesical BCG treatments. Patients received 12 instillations during 5-6 months. No immediate postoperative instillation or second TUR were performed in these patients. The scoring system is based on evaluation of seven prognostic parameters:

- patients' sex;
- patients' age;
- recurrence status;
- number of tumours;
- T-category;
- associated CIS;
- tumour grade.

Using these tables, the calculated risk of recurrence is lower than that obtained by the EORTC tables. For progression probabilities, it is lower only in high-risk patients (107). The lower risks in the CUETO tables may be attributed to using a more effective instillation therapy in the individual studies on which the CUETO tables are based. The validation of the EORTC scoring system in an independent patient population with long-term follow-up has confirmed its prognostic value (108).

## 6.2 Carcinoma *in situ*

Without any treatment, approximately 54% of patients with CIS progress to muscle-invasive disease (109). Unfortunately, there are no reliable prognostic factors that can be used to predict the course of the disease and specify the most dangerous cases. The publications are based on a retrospective analysis of small series of patients and their conclusions are not homogeneous. Some studies have reported worse prognosis in concurrent CIS and T1 tumours compared to primary CIS (110,111) and in extended CIS (112) (LE: 3).

Various publications have shown that the response to intravesical treatment with BCG or chemotherapy is an important prognostic factor for subsequent progression and death caused by bladder cancer (113-116). Approximately 10-20% of complete responders eventually progress to muscle-invasive disease, compared with 66% of non-responders (113-115) (LE: 2).

# 7. ADJUVANT TREATMENT

## 7.1 Intravesical chemotherapy

Although state-of-the-art TUR by itself can eradicate a TaT1 tumour completely, these tumours recur in a high percentage of cases and progress to muscle-invasive bladder cancer in a limited number of cases. The high variability in the 3-month recurrence rate indicates that TUR is incomplete or provokes recurrences in a high percentage of patients (78). It is therefore necessary to consider adjuvant therapy in all patients. The absolute risks of recurrence and progression do not always indicate the risk at which a certain therapy is optimal. The choice of therapy may be considered differently according to what risk is acceptable for the individual patient and the urologist.

### 7.1.1 *One, immediate, postoperative intravesical instillation of chemotherapy*

In a meta-analysis of seven randomised trials (1,476 patients with a median follow-up of 3.4 years), one immediate instillation of chemotherapy after TUR significantly reduced recurrence rate compared to TUR alone (LE: 1a) (117). In absolute values, the reduction was 11.7% (from 48.4% to 36.7%), which implies a 24.2%

decrease in the corresponding relative risk. The majority of patients (> 80%) in the meta-analysis had a single tumour, but an almost significant and even greater reduction in recurrence was noted among the limited number of patients with multiple tumours. The efficacy of the single instillation has been confirmed also by two recently published studies (118,119). In one of these (119), the benefit was mainly seen in primary and single tumours and was in these tumour categories even greater than the 11.7%. By stratification according to EORTC recurrence scores, the benefit was observed in patients with scores 0-2, but not with scores  $\geq 3$ . However, the study was not sufficiently powered for subgroup analyses. Despite stratification at randomisation, no separate analysis was made for primary or recurrent tumours in the other study (118).

No prospective data are available showing that the single instillation significantly reduces recurrence rates in patients with recurrent tumours. Nevertheless, there is significant evidence from one subgroup analysis that an immediate instillation might have an impact on the repeat instillation regimen for treatment of patients who are at intermediate- and high risk of recurrence (120) (LE: 2a). There are no statistically relevant data that address the role of immediate chemotherapy instillation in tumours at high risk of progression before further BCG intravesical treatment.

In summary, one immediate instillation significantly reduces the risk of recurrence in TaT1 bladder tumours. Further studies are required, however, to determine the definitive role of immediate chemotherapy before BCG or further chemotherapy instillations in intermediate- and high-risk groups.

The effect of early instillation can be explained by the destruction of circulating tumour cells immediately after TUR, or as an ablative effect (chemoresection) of residual tumour cells at the resection site. Prevention of tumour cell implantation should be initiated within the first hours after cell seeding. Within a few hours, the cells are implanted firmly and are covered by extracellular matrix (121-124). In all single instillation studies, the instillation was administered within 24 h. Subgroup analysis of one study has shown that, if the first instillation was not given on the same day as TUR, there was a twofold increase in the relative risk of recurrence (120) (LE: 2a). Moreover, a study in which the instillation was not given strictly on the same day did not find any advantage (125). To maximise the efficacy of the immediate instillation, every effort should be made to create flexible practices that allow the instillation to be given when necessary and as early as possible, that is, in the recovery room or even in the operating theatre.

There is no single drug that is superior with regard to efficacy. Mitomycin C, epirubicin, and doxorubicin have all shown a beneficial effect (117) (LE: 1a). In one study, gemcitabine plus 24 h bladder irrigation with physiological saline was not superior to irrigation with physiological saline alone (126) (LE: 1b).

The guidelines expert panel recommends immediate instillation in tumours at low risk of progression (single, primary, papillary lesions) as the only intravesical treatment and in those presumably at intermediate risk, for which a single instillation is considered as the initial stage of further intravesical therapy. In tumours that are presumably at high risk of progression (solid lesions, positive urinary cytology), immediate instillation is an option because it can have a positive impact on recurrence rate through prevention of tumour cell implantation. However, there is no doubt that subsequent BCG intravesical immunotherapy is essential treatment in these patients (see lower).

The immediate post-operative chemotherapy instillation should be omitted in any case of overt or suspected intra- or extraperitoneal perforation, which is most likely to appear in extensive TUR procedures, and in situations with bleeding requiring bladder irrigation. Severe complications have been reported in patients in whom extravasation of the drug occurs (127).

Clear instructions should be given to the nursing staff to control the free flow of the bladder catheter at the end of the instillation. It has been demonstrated that administration of instillation is possible in the majority of cases (128).

### **7.1.2 Additional adjuvant intravesical chemotherapy instillations**

The need for further adjuvant intravesical therapy depends on the patients' prognosis. In patients with a low risk of tumour recurrence (see Table 7), a single immediate instillation reduces the risk of recurrence and is considered as the standard treatment (117) (LE: 1a). No further treatment should be given in these patients before subsequent recurrence. For other patients, however, a single immediate instillation remains an incomplete treatment because the likelihood of recurrence and/or progression is considerable.

The effect of the immediate instillation of chemotherapy occurs during the first and second year (129,130) (LE: 1b). It has been calculated from the data of five randomised trials (130) that the reduction of recurrence lasts for a period of approximately 500 days.

The choice between further chemotherapy or immunotherapy largely depends on the risk that needs to be reduced: recurrence or progression. A combined analysis of EORTC and Medical Research Council data, comparing intravesical chemotherapy to TUR alone, has demonstrated that chemotherapy prevents recurrence but not progression (131) (LE: 1a). The efficacy of intravesical chemotherapy in reducing the risk of tumour recurrence has been confirmed by two other meta-analyses in primary (132) and recurrent tumours (133).



It is still controversial how long and how frequently instillations of intravesical chemotherapy have to be given. From a systematic review of the literature of randomised clinical trials, which have compared different schedules of intravesical chemotherapy instillations, one can only conclude that the ideal duration and intensity of the schedule remains undefined because of conflicting data (134). Nevertheless, the available evidence does not support any treatment longer than 1 year.

### **7.1.3 Optimising intravesical chemotherapy**

One randomised trial has demonstrated that adapting urinary pH, decreasing urinary excretion, and buffering the intravesical solution reduce the recurrence rate (135) (LE: 1b).

Another randomised trial has documented that concentration is more important than duration of the treatment (136) (LE: 1b). In view of these data, which need confirmation, it seems advisable to ask the patient not to drink on the morning before instillation, and to dissolve the drug in a buffered solution at optimal pH.

## **7.2 Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy**

### **7.2.1 Efficacy of BCG**

Several meta-analyses have addressed important questions concerning the efficacy of BCG in non-muscle-invasive bladder tumours. Four meta-analyses have confirmed that BCG after TUR is superior to TUR alone or TUR and chemotherapy for prevention of recurrence of non-muscle-invasive tumours (137-140) (LE: 1a). Since the publication of these meta-analyses, three randomised studies of intermediate- and high-risk tumours have been presented. In these studies, BCG was compared with the combination of epirubicin and interferon (141), mitomycin C (MMC) (142) or epirubicin (143) alone. All of these studies have confirmed the superiority of BCG for prevention of tumour recurrence. It has been shown that the effect was long lasting (142,143) and was also observed in a separate analysis of patients with tumours at intermediate risk (143).

One recently published meta-analysis (144) has evaluated the individual data from 2,820 patients enrolled in nine randomised studies that have compared MMC versus BCG. In the trials with BCG maintenance, a 32% reduction in the risk of recurrence for BCG compared to MMC was found ( $p < 0.0001$ ), whereas there was a 28% increase in the risk of recurrence ( $p = 0.006$ ) for patients treated with BCG in the trials without BCG maintenance.

Two meta-analyses have demonstrated that BCG therapy prevents, or at least delays, the risk of tumour progression (145,146) (LE: 1a). A meta-analysis carried out by the EORTC-GU group has evaluated data from 4,863 patients enrolled in 24 randomised trials. A total of 3,967 (81.6%) patients had only papillary tumours and 896 (18.4%) had primary or concurrent CIS. Five different BCG strains were used, and in 20 out of the 24 trials, some form of BCG maintenance was used. In four trials only, a 6-week induction course was used. Based on a median follow-up of 2.5 years and a maximum of 15 years, 260 out of 2,658 patients (9.8%) on BCG progressed compared to 304 out of 2,205 (13.8%) in the control groups (TUR alone, TUR plus intravesical chemotherapy, or TUR plus other immunotherapy). This shows a reduction of 27% in the odds of progression with BCG maintenance treatment ( $p = 0.0001$ ). The size of the reduction is similar in patients with TaT1 papillary tumours and in those with CIS (146). A recent randomised study with long-term observation has demonstrated significantly fewer distant metastases and better overall- and disease-specific survival in patients treated with BCG compared to epirubicin (143) (LE: 1b). On the contrary, a meta-analysis of individual patient data was not able to confirm any statistically significant difference between MMC and BCG for progression, survival and cause of death (144). In summary, in spite of these conflicting results, the majority of data was able to show the reduction in the risk of progression in tumours at high and intermediate risk if the BCG including maintenance schedule was used.

Two other meta-analyses have suggested a possible bias in favour of BCG by the inclusion of patients who were previously treated with intravesical chemotherapy (147,148). In the most recent meta-analysis, however, BCG maintenance was more effective than MMC also in patients who were previously treated with chemotherapy (144).

### **7.2.2 Optimal BCG schedule**

For optimal efficacy, BCG must be given in a maintenance schedule (140,144-146) (LE: 1a). In the EORTC-GU group meta-analysis, only patients who received maintenance BCG benefited. In the four trials in which no maintenance was given, no reduction in progression was observed. In the 20 trials in which some form of BCG maintenance was given, a reduction of 37% in the odds of progression was observed ( $p = 0.00004$ ). The meta-analysis was unable to determine which BCG maintenance schedule was the most effective (146). In their meta-analysis, Böhle et al. have concluded that at least 1 year of maintenance BCG is required to obtain the superiority of BCG over MMC for prevention of recurrence or progression (140,145). Although some modifications have been tried, induction BCG instillations are classically given according to the empirical 6-weekly induction schedule that was introduced by Morales in 1976 (149). However, many different maintenance schedules have been used, ranging from a total of 10 instillations given in 18 weeks, to 27

instillations over 3 years (150). The optimal number of induction instillations and the optimal frequency and duration of maintenance instillations remain unknown (151).

### 7.2.3 **Optimal dose of BCG**

To reduce BCG toxicity, a number of authors have proposed one-third and one-quarter dose instillations of BCG. Comparing one-third dose to full-dose BCG in 500 patients, CUETO has found no overall difference in efficacy. However, it has been suggested that a full dose of BCG is more effective in multifocal tumours (152,153) (LE: 1b). Although fewer patients have reported toxicity with the reduced dose, the incidence of severe systemic toxicity has been similar in the standard- and reduced-dose groups. The same Spanish group has shown in a prospective randomised trial that one-third of the standard dose of BCG might be the minimum effective dose in intermediate-risk tumours. A further reduction to one-sixth dose resulted in a decrease in efficacy for prevention of recurrence with no decrease in toxicity (154).

### 7.2.4 **BCG toxicity**

Assuming that maintenance therapy is necessary for optimal efficacy, the issue of BCG toxicity becomes more relevant. As a result of the more pronounced side effects of BCG compared to intravesical chemotherapy, there is still reluctance about the use of BCG. Deaths due to BCG sepsis and the high frequency of BCG-induced cystitis and allergic reactions have compromised its use (155). However, with increased experience in using BCG, the side effects now appear to be less prominent. Serious side effects are encountered in < 5% of patients and can be effectively treated in virtually all cases (155) (LE: 1b). Major complications can appear after systemic absorption of the drug. Thus, BCG should not be administered during the first 2 weeks after TUR, in patients with macroscopic haematuria or urinary tract infection, or after traumatic catheterisation. It should not be used in immunocompromised patients (immunosuppression, human immunodeficiency virus [HIV]) (156).

The management of side-effects after BCG should reflect their type and grade. Recommendations for individual situations were provided by the International Bladder Cancer Group and by a Spanish group (157,158). Before applying intravesical BCG therapy the urologist should be aware how to treat BCG-induced complications.

### 7.2.5 **Indications for BCG**

Although BCG is a very effective treatment, there is a consensus that not all patients with non-muscle-invasive bladder cancer should be treated with BCG due to the risk of toxicity. Ultimately, the choice of treatment depends upon the patients' risk of recurrence and progression (see Table 7). The use of BCG does not alter the natural course of tumours at low risk of recurrence (see Table 7), and could be considered to be over-treatment for this patient category. In patients with tumours at high risk of progression, for whom cystectomy is not carried out, BCG including at least 1 year maintenance is indicated. In patients at intermediate or high risk of recurrence and intermediate risk of progression, BCG with 1 year maintenance is more effective than chemotherapy for prevention of recurrence; however, it has more side effects than chemotherapy. For this reason both BCG with maintenance and intravesical chemotherapy remain an option. The final choice should reflect the individual patients' risk of recurrence and progression as well as efficacy and side effects of each treatment modality.

## 7.3 **Specific aspects of treatment of CIS**

### 7.3.1 **Treatment strategy**

If concurrent CIS is found in association with muscle-invasive bladder cancer, therapy is determined according to the invasive tumour. The detection of CIS with TaT1 tumours increases the risk of recurrence and progression of TaT1 tumours (106,107) and further treatment is mandatory. The treatment strategy is generally based on the criteria that are summarised in Sections 7.1, 7.2, 7.4 and Chapter 8.

Carcinoma *in situ* cannot be cured by an endoscopic procedure only. Histological diagnosis of CIS must be followed by further treatment, either intravesical BCG instillations or radical cystectomy (LE: 2). No consensus exists about whether conservative therapy (intravesical BCG instillations) or aggressive therapy (cystectomy) should be done, especially when there are concurrent high-grade papillary tumours. There has been a lack of randomised trials of instillation therapy and early cystectomy as immediate primary treatment. Tumour-specific survival rates after early cystectomy for CIS are excellent, but as many as 40-50% of patients might be over-treated (3).

### 7.3.2 **Cohort studies**

In retrospective evaluations of patients with CIS, a complete response rate of 48% was achieved with intravesical chemotherapy and 72-93% with BCG (109-112,159) (LE: 2). Up to 50% of complete responders might eventually show recurrence with a risk of invasion and/or extravesical recurrence (112,150,159,160).

### 7.3.3 **Prospective randomised trials**

Unfortunately, there have been few randomised trials in patients with CIS alone. Most trials have included patients with either papillary tumours or CIS, which has resulted in only a small number of CIS patients being entered. Thus, the power to detect differences of treatment results has been low and the reliability of the conclusions is limited (3).

A meta-analysis of clinical trials that has compared intravesical BCG to intravesical chemotherapy (MMC, epirubicin, or adriamycin) in patients with CIS has shown a significantly increased response rate after BCG and a reduction of 59% in the odds of treatment failure with BCG (OR = 0.41,  $p = 0.0001$ ). In trials that have compared BCG with MMC, the long-term benefit of BCG was smaller, but BCG was superior to MMC in trials with BCG maintenance (OR = 0.57,  $p = 0.04$ ) (161).

In an EORTC-GU group meta-analysis of tumour progression, in a subgroup of 403 patients with CIS, BCG reduced the risk of progression by 35% as compared to intravesical chemotherapy or different immunotherapy (OR = 0.65, 95% CI = 0.36-1.16,  $p = 0.10$ ) (146) (LE: 1b). There has been no single trial that has demonstrated superiority of combined BCG and MMC over BCG alone (162) (LE: 1).

In summary, as compared to chemotherapy, treatment of patients with CIS using BCG increases the complete response rate, the overall percentage of patients who remain disease free, and reduces the risk of tumour progression (LE: 1a).

### 7.3.4 **Treatment of extravesical CIS**

Patients with CIS are at high risk of extravesical involvement: in the upper urinary tract and in the prostatic urethra. Solsona et al. have found that 87 of 138 patients (63%) with CIS developed extravesical involvement initially or during follow-up (163). Patients with extravesical involvement had worse survival than those with bladder CIS alone (163) (LE: 3).

In the prostate, CIS might be present only in the epithelial lining of the prostatic urethra or in the prostatic ducts (3). These situations should be distinguished from tumour invasion into the stroma of the prostate, which is staged as T4a, and for which immediate cystoprostatectomy is mandatory. Patients with CIS in the epithelial lining of the prostatic urethra can be treated by intravesical instillations of BCG. Transurethral resection of the prostate can improve the contact of BCG with the prostatic urethra (3,164,165) (LE: 3). In patients with prostatic duct involvement, the data are insufficient to provide clear treatment recommendations. As no conclusive results have been attained with regard to the use of conservative therapy, radical surgery should be considered in these patients (165) (LE: 3).

The treatment of CIS that involves the upper urinary tract is discussed in the upper urinary tract guidelines.

## 7.4 **Treatment of failure of intravesical therapy**

### 7.4.1 **Failure of intravesical chemotherapy**

Patients with non-muscle-invasive recurrence of urothelial bladder carcinoma after intravesical chemotherapy can profit from BCG instillations (147) (LE: 1a).

### 7.4.2 **Failure of intravesical BCG immunotherapy**

Treatment with BCG is considered to have failed in following situations:

- a. Whenever muscle-invasive tumour is detected during follow-up.
- b. If high-grade, non-muscle-invasive tumour is present at both 3 and 6 months (166). In patients with tumour present at 3 months, an additional BCG course can achieve a complete response in > 50% of cases, both in patients with papillary tumours and CIS (37,166), but with increasing risk of progression (167,168).
- c. Any worsening of the disease under BCG treatment, such as a higher number of recurrences, higher T- stage or higher grade, or appearance of CIS, in spite of an initial response (LE: 3).

Changing from BCG to intravesical chemotherapy, device-assisted chemotherapy instillations, or additional interferon  $\alpha$ -2b immunotherapy can yield responses in selected cases with non-muscle-invasive BCG treatment failure (169-178). However, experience is limited and these strategies are considered experimental. As a result of the high risk of development of muscle-invasive tumour in these patients (166-168) (LE: 3), cystectomy is strongly advocated upon early BCG failure in fit patients.

Patients with a recurrence at > 1 year after completion of BCG therapy can be treated according to the risk classification (See Tables 6, 7 and 8) (169).

**Table 8: Treatment recommendations in TaT1 tumours according to risk stratification**

Risk category	Low	Intermediate	High
Recurrence	One immediate instillation of chemotherapy	One immediate instillation of chemotherapy, followed by further instillations, either chemotherapy or a minimum 1 year of BCG (the final choice is determined by the risk of tumour progression)	One immediate instillation of chemotherapy, followed by further instillations, either chemotherapy or a minimum of 1 year of BCG (the final choice is determined by the risk of tumour progression)
Progression	One immediate instillation of chemotherapy (it can be followed by further chemotherapy instillations if the patients has at the same time an intermediate risk of recurrence)	One immediate instillation of chemotherapy, followed by a minimum of 1 year of BCG or further chemotherapy instillations	Intravesical BCG for at least 1 year, or immediate cystectomy

BCG = *bacillus Calmette-Guérin*.

### 7.5 Recommendations for adjuvant therapy in TaT1 tumours and for therapy of CIS

	GR
The type of intravesical therapy should be based on the risk groups shown in Table 7.	A
In patients with TaT1 tumours at low risk of recurrence and progression, one immediate instillation of chemotherapy is recommended as the complete adjuvant treatment.	A
In patients with TaT1 tumours at intermediate or high risk of recurrence and intermediate risk of progression, one immediate instillation of chemotherapy should be followed by a minimum 1 year of BCG treatment, or by further instillations of chemotherapy.	A
If chemotherapy is given, it is advised to use the drug at its optimal pH and to maintain the concentration of the drug during instillation by reducing fluid intake. The optimal schedule and the duration of the chemotherapy instillations remain unclear, but it should be given no more than 12 months.	B
In patients with TaT1 tumours at high risk of progression, intravesical BCG for at least 1 year is indicated.	A
In patients with bladder CIS, intravesical BCG for at least 1 year is indicated.	A
In patients with CIS in the epithelial lining of the prostatic urethra, TUR of the prostate followed by intravesical instillations of BCG could be an option.	C
Immediate radical cystectomy may be offered to patients at highest risk of tumour progression.	C
In patients with BCG failure, cystectomy is indicated.	B

BCG = *bacillus Calmette-Guérin*; CIS = *carcinoma in situ*; TUR = *transurethral resection*.

## 8. CYSTECTOMY FOR NON-MUSCLE-INVASIVE BLADDER CANCER

Some experts consider it is reasonable to propose immediate cystectomy to those patients with non-muscle-invasive tumour who are at high risk of progression. According to the risk tables of the EORTC (see Tables 6 and 7) these are:

- multiple recurrent high-grade tumours;
- high-grade T1 tumours;
- high-grade tumours with concurrent CIS.

With these patients, it is recommended to discuss both treatment options: immediate cystectomy and conservative treatment with BCG instillations. Patients should be informed about the benefits and risks of both approaches.

Cystectomy is advocated in patients with non-muscle-invasive tumours with BCG treatment failure, as mentioned above. Delay of cystectomy in these patients might lead to decreased disease-specific survival (179). In patients in whom cystectomy is performed at the time of pathological non-muscle-invasive disease, the 5-year disease-free survival rate exceeds 80% (180-185).

## 9. FOLLOW-UP OF PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER TUMOURS

As a result of the risk of recurrence and progression, patients with TaT1 bladder tumours need to be followed; however, the frequency and duration of cystoscopy and imaging should reflect the individual patients' degree of risk. Using risk tables (see Tables 6 and 7), we are able to predict the short-term and long-term risks of recurrence and progression in individual patients, and can adapt the follow-up schedule accordingly (106). By planning the follow-up schedule the following aspects should be considered:

- The prompt detection of muscle-invasive and high-grade non-muscle-invasive recurrence is crucial because a delay in diagnosis and therapy can be life-threatening to the patient.*
- Tumour recurrence in the low-risk group is nearly always low stage and low grade.*  
Small, non-invasive (Ta), low-grade papillary recurrence does not present an immediate danger to the patient, and early detection is not essential for successful therapy (186-193) (LE: 2b). In these patients, fulguration of small papillary recurrences on an outpatient basis could be a safe treatment option that reduces the therapeutic burden (194) (LE: 3). Some authors even defend temporary surveillance (192,193,195).
- The result of the first cystoscopy after TUR at 3 months is a very important prognostic indicator for recurrence and progression (106,168,196,197) (LE: 1a).* The first cystoscopy should thus **always** be performed 3 months after TUR in all patients with TaT1 bladder tumour.
- The risk of upper urinary tract recurrence increases in patients with multiple and high risk tumours (42) (LE: 3).*

As there has not been presented any non-invasive method that could replace endoscopy, the follow-up is based on regular cystoscopies (see 5.5). There has been a lack of randomised studies that have investigated the possibility of safely reducing frequency of follow-up cystoscopies. The following recommendations are therefore based only on retrospective experience.

## 9.1 Recommendations for follow-up in patients after TUR of non-muscle-invasive bladder cancer

	GR
Patients with TaT1 tumours at low risk of recurrence and progression should have a cystoscopy at 3 months. If negative, the following cystoscopy is advised 9 months later, and then yearly for 5 years.	C
Patients with TaT1 tumours at high risk of progression and those with CIS should have a cystoscopy and urinary cytology at 3 months. If negative, the following cystoscopy and cytology should be repeated every 3 months for a period of 2 years, and every 6 months thereafter until 5 years, and then yearly. Yearly imaging of the upper tract is recommended.	C
Patients with TaT1 tumours at intermediate risk of progression (about one-third of all patients) should have an in-between follow-up scheme using cystoscopy and cytology, which is adapted according to personal and subjective factors.	C
During follow-up in patients with positive cytology and no visible tumour in the bladder, R-biopsies or biopsies with PDD (if equipment is available) and investigation of extravesical locations (CT urography, prostatic urethra biopsy) are recommended.	B

*CIS* = carcinoma in situ; *PDD* = photodynamic diagnosis.

## 10. REFERENCES

- Oosterlinck W, Lobel B, Jakse G, et al; European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. *Eur Urol* 2002 Feb;41(2):105-12.  
<http://www.ncbi.nlm.nih.gov/pubmed/12074395>
- Oosterlinck W, Solsona E, van der Meijden APM, et al; European Association of Urology. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. *Eur Urol* 2004 Aug;46(2):147-54.  
<http://www.ncbi.nlm.nih.gov/pubmed/15245806>
- Van der Meijden APM, Sylvester R, Oosterlinck W, et al; for the EAU Working Party on Non Muscle Invasive Bladder Cancer. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. *Eur Urol* 2005 Sep;48(3):363-71.  
<http://www.ncbi.nlm.nih.gov/pubmed/15994003>
- Babjuk M, Oosterlinck W, Sylvester R, et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. *Eur Urol* 2008 Aug;54(2):303-14.  
<http://www.ncbi.nlm.nih.gov/pubmed/18468779>
- Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2009). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009.  
<http://www.cebm.net/index.aspx?o=1025> [Access date January 2012]
- Atkins D, Best D, Briss PA, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations. *BMJ* 2004 Jun 19;328(7454):1490.  
<http://www.ncbi.nlm.nih.gov/pubmed/15205295>
- Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336(7650):924-6.  
<http://www.ncbi.nlm.nih.gov/pubmed/18436948>
- Guyatt GH, Oxman AD, Kunz R et al; GRADE Working Group. Going from evidence to recommendations. *BMJ* 2008 May 10;336(7652):1049-51.  
<http://www.bmj.com/content/336/7652/1049.full>
- Ploeg M, Aben KKH, Kiemeny LA. The present and future burden of urinary bladder cancer in the world. *World J Urol* 2009 Jun;27(3):289-93.  
<http://www.ncbi.nlm.nih.gov/pubmed/19219610>
- Ferlay J, Bray F, Pisani P, et al. *Globocan 2002, Cancer Incidence, Mortality and Prevalence Worldwide*, IARC CancerBase No. 5, version 2.0. Lyon: IARC Press, 2004.
- Ferlay J, Randi G, Bosetti C, et al. Declining mortality from bladder cancer in Europe. *BJU Int* 2008 Jan;101(1):11-19.  
<http://www.ncbi.nlm.nih.gov/pubmed/17971176>

12. McCahy PJ, Harris CA, Neal E. The accuracy of recording of occupational history in patients with bladder cancer. *Br J Urol* 1997 Jan;79(1):91-3.  
<http://www.ncbi.nlm.nih.gov/pubmed/9043504>
13. Zeegers MPA, Swaen GMH, Kant I, et al. Occupational risk factors for male bladder cancer: results from a population-based case cohort study in the Netherlands. *Occup Environ Med* 2001 Sep;58(9):590-6.  
<http://www.ncbi.nlm.nih.gov/pubmed/11511746>
14. Samanic CM, Kogevinas M, Silverman DT et al. Occupation and bladder cancer in a hospital-based case-control study in Spain. *Occup Environ Med* 2008 May;65(5):347-53.  
<http://www.ncbi.nlm.nih.gov/pubmed/17951336>
15. Zeegers MP, Tan FE, Dorant E, et al. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. *Cancer* 2000 Aug;89(3):630-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/10931463>
16. Bjerregaard BK, Raaschou-Nielsen O, Sørensen M, et al. Tobacco smoke and bladder cancer-in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* 2006 Nov;119(10):2412-6.  
<http://www.ncbi.nlm.nih.gov/pubmed/16894557>
17. Puente D, Harge P, Greiser E et al. A pooled analysis of bladder cancer case-control studies evaluating smoking in men and women. *Cancer Causes Contr* 2006 Feb;17(1):71-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/16411055>
18. Aveyard P, Adab P, Cheng KK, et al. Does smoking status influence the prognosis of bladder cancer? A systematic review. *BJU Int* 2002 Aug;90(3):228-39.  
<http://www.ncbi.nlm.nih.gov/pubmed/12133057>
19. Sobin LH, Gospodariwicz M, Wittekind C (eds). TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, 2009 Dec; pp. 262-265.  
<http://www.uicc.org/tnm/>
20. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. *Am J Surg Pathol* 1998 Dec;22(12):1435-48.  
<http://www.ncbi.nlm.nih.gov/pubmed/9850170>
21. Sauter G, Algaba F, Amin M, et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein JI, Sesterhenn I, eds. *WHO classification of classification of tumours of the urinary system and male genital organs*. Lyon: IARCC Press, 2004, pp. 29-34.
22. Pan CC, Chang YH, Chen KK, et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. *Am J Clin Pathol* 2010 May;133(5):788-95.  
<http://www.ncbi.nlm.nih.gov/pubmed/20395527>
23. Burger M, van der Aa MN, van Oers JM, et al. Prediction of Progression of Non Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. *Eur Urol* 2008 Oct;54(4):835-44.  
<http://www.ncbi.nlm.nih.gov/pubmed/18166262>
24. May M, Brookman-Amisshah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation Classifications. *Eur Urol* 2010 May;57(5):850-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/19346063>
25. Otto W, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. *BJU Int* 2011 Feb;107(3):404-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/20707791>
26. MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. *Eur Urol* 2007 Apr;51(4):889-98.  
<http://www.ncbi.nlm.nih.gov/pubmed/17095142>
27. Orsola A, Trias I, Raventós CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. *Eur Urol*. 2005 Aug;48(2):231-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/15963635>
28. Andius P, Johansson SL, Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. *Urology* 2007 Oct;70(4):758-62.  
<http://www.ncbi.nlm.nih.gov/pubmed/17991551>

29. Faivre d'Arcier B, et al. T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU). *Prog Urol*. 2010 Jun;20(6):440-9. [Article in French]  
<http://www.ncbi.nlm.nih.gov/pubmed/20538209>
30. Cho KS, Seo HK, Joung JY et al. Lymphovascular Invasion in Transurethral Resection Specimens as Predictor of Progression and Metastasis in Patients With Newly Diagnosed T1 Bladder Urothelial Cancer. *J Urol* 2009 Dec;182(6):2625-31.  
<http://www.ncbi.nlm.nih.gov/pubmed/19836779>
31. Kamat AM. The Case for Early Cystectomy in the Treatment of Nonmuscle Invasive Micropapillary Bladder Carcinoma. *J Urol* 2006 Mar;175(3 Pt 1):881-5.  
<http://www.ncbi.nlm.nih.gov/pubmed/16469571>
32. Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 WHO/ISUP classification of urothelial neoplasms: practical choices for patient care. *J Urol* 2002 Sep;168(3):968-72.  
<http://www.ncbi.nlm.nih.gov/pubmed/12187201>
33. Witjes JA, Moonen PMJ, van der Heijden AG. Review pathology in a diagnostic bladder cancer trial. *Urology* 2006 Apr;67(4):751-5.  
<http://www.ncbi.nlm.nih.gov/pubmed/16566990>
34. Bol MG, Baak J, Buhr-Wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. *J Urol* 2003 Apr;169(4):1291-4.  
<http://www.ncbi.nlm.nih.gov/pubmed/12629345>
35. Van der Meijden A, Sylvester R, Collette L, et al. The role and impact of pathology review on stage and grade assessment on stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials. *J Urol* 2000 Nov;164(5):1533-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/11025698>
36. Van Rhijn BWG, van der Kwast TH, Kakiashvili DM, et al. Pathological stage review is indicated in primary pT1 bladder cancer. *BJU Int* 2010 Jul;106(2):206-11.  
<http://www.ncbi.nlm.nih.gov/pubmed/20002439>
37. Sylvester R, van der Meijden A, Witjes JA, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. *Urology* 2005 Dec;66(6 Suppl 1):90-107.  
<http://www.ncbi.nlm.nih.gov/pubmed/16399418>
38. Lamm DL, Herr HW, Jakse G, et al. Updated concepts and treatment of carcinoma in situ. *Urol Oncol* Jul-Oct 1998;4(4-5):130-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/21227218>
39. Goessl C, Knispel HH, Millar K, et al. Is routine excretory urography necessary at first diagnosis of bladder cancer? *J Urol* 1997 Feb;157(2):480-1.  
<http://www.ncbi.nlm.nih.gov/pubmed/8996338>
40. Palou J, Rodriguez-Rubio F, Huguet J, et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumours. *J Urol* 2005 Sep;174(3):859-61.  
<http://www.ncbi.nlm.nih.gov/pubmed/16093970>
41. Holmang S, Hedelin H, Anderstrom C, et al. Long-term follow-up of a bladder carcinoma cohort: routine followup urography is not necessary. *J Urol* 1998 Jul;160(1):45-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/9628602>
42. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al. Upper urinary tract tumours after primary superficial bladder tumours: prognostic factors and risk groups. *J Urol* 2000 Oct;164(4):1183-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/10992362>
43. Nolte-Ernsting C, Cowan N. Understanding multislice CT urography techniques: many roads lead to Rome. *Eur Radiol* 2006 Dec;16(12):2670-86.  
<http://www.ncbi.nlm.nih.gov/pubmed/16953373>
44. Raitanen M-P, Aine R, Rintala E, et al; FinnBladder Group. Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis. *Eur Urol* 2002;41(3):284-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/12180229>
45. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumour markers beyond cytology: international consensus panel on bladder tumour markers. *Urology* 2005 Dec;66(6 Suppl 1):35-63.  
<http://www.ncbi.nlm.nih.gov/pubmed/16399415>



46. Glas AS, Roos D, Deutekom M, et al. Tumour markers in the diagnosis of primary bladder cancer. A systematic review. *J Urol* 2003 Jun;169(6):1975-82.  
<http://www.ncbi.nlm.nih.gov/pubmed/12771702>
47. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumour markers versus cytology: results of a comprehensive literature review and meta-analysis. *Urology* 2003 Jan;61(1):109-18.  
<http://www.ncbi.nlm.nih.gov/pubmed/12559279>
48. Van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. *Eur Urol* 2005 Jun;47(6):736-48.  
<http://www.ncbi.nlm.nih.gov/pubmed/15925067>
49. Van Rhijn BWG, van der Poel HG, van der Kwast HG. Cytology and urinary markers for the diagnosis of bladder cancer. *Eur Urol Suppl* 2009;8:536-41.
50. Vrooman OPJ, Witjes JA. Urinary markers in bladder cancer. *Eur Urol* 2008 May;53(5):909-16.  
<http://www.ncbi.nlm.nih.gov/pubmed/18162285>
51. Lotan Y, Shariat SF, Schmitz-Drager BJ, et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. *Urol Oncol* 2010 Jul-Aug;28(4):441-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/20610281>
52. Yutkin V, Nisman B, Pode D. Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance? *Expert Rev Anticanc* 2010 Jun;10(6):787-90.  
<http://www.ncbi.nlm.nih.gov/pubmed/20553203>
53. Zwarthoff EC. Detection of tumours of the urinary tract in voided urine. *Scand J Urol Nephrol* 2008 Sep;(218):147-53.  
<http://www.ncbi.nlm.nih.gov/pubmed/18815929>
54. Shirodkar SP, Lokeshwar VB. Bladder tumor markers: from hematuria to molecular diagnostics - where do we stand? *Expert Rev Anticanc* 2008 Jul;8(7):1111-23.  
<http://www.ncbi.nlm.nih.gov/pubmed/18588456>
55. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. *Curr Opin Urol*. 2008 Jan;18(1):1-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/18090481>
56. Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. *Cancer Sci* 2008 Apr;99(4):646-52.  
<http://www.ncbi.nlm.nih.gov/pubmed/18377416>
57. Catto JWF. Old and new urinary markers: Which one is the PSA for bladder cancer? *Eur Urol Suppl*. 2008;7:422-5.
58. Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. *World J Urol* 2008 Feb;26(1):39-44.  
<http://www.ncbi.nlm.nih.gov/pubmed/18092171>
59. Kausch I, Böhle A. Bladder cancer II. Molecular aspects and diagnosis. *Eur Urol* 2001 May;39(5):498-506.  
<http://www.ncbi.nlm.nih.gov/pubmed/11464029>
60. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay, *JAMA* 2005 Feb 29;293(7):810-6.  
<http://www.ncbi.nlm.nih.gov/pubmed/15713770>
61. Lotan Y, Svatek RS, Malats N. Screening for bladder cancer: a perspective. *World J Urol* 2008 Feb;26(1):13-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/18030473>
62. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. *JAMA* 2006 Jan;295(3):299-305.  
<http://www.ncbi.nlm.nih.gov/pubmed/16418465>
63. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. *Urol Oncol* 2008 Nov-Dec;26(6):645-51.  
<http://www.ncbi.nlm.nih.gov/pubmed/18367109>
64. Mowatt G, Zhu S, Kilonzo M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. *Health Technol Assess* 2010 Jan;14(4):1-331.  
<http://www.ncbi.nlm.nih.gov/pubmed/20082749>
65. Babjuk M, Soukup V, Pesl M, et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pT1 bladder urothelial carcinoma. *Urology* 2008 Apr;71(4):718-22.  
<http://www.ncbi.nlm.nih.gov/pubmed/18387400>

66. Raitanen MP. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. *World J Urol* 2008 Feb;26(1):45-50.  
<http://www.ncbi.nlm.nih.gov/pubmed/18180926>
67. Lotan Y, Shariat SF, Grp NS. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. *BJU Int* 2008 Jun;101(11):1362-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/18284410>
68. Shariat SF, Marberger MJ, Lotan Y, et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. *J Urology* 2006 Sep;176(6):919-26.  
<http://www.ncbi.nlm.nih.gov/pubmed/16890655>
69. Nguyen CT, Jones JS. Defining the role of NMP22 in bladder cancer surveillance. *World J Urol* 2008 Feb;26(1):51-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/18058108>
70. Schmitz-Drager BJ, Beiche B, Tirsar LA, et al. Immunocytology in the assessment of patients with asymptomatic microhaematuria. *Eur Urol* 2007 Jun;51(6):1582-8; discussion 8.  
<http://www.ncbi.nlm.nih.gov/pubmed/17107748>
71. Schlomer BJ, Ho R, Sagalowsky A, et al. Prospective Validation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder. *J Urol* 2010 Jan;183(1):62-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/19913822>
72. Bergman J, Reznichak RC, Rajfer J. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. *BJU Int* 2008 Jan;101(1):26-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/17850364>
73. Van der Aa MN, Zwarthoff EC, Steyerberg EW, et al. Microsatellite Analysis of Voided-Urine Samples for Surveillance of Low-Grade Non-Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). *Eur Urol* 2009 Mar;55(3):659-67.  
<http://www.ncbi.nlm.nih.gov/pubmed/18501499>
74. De Bekker-Grob EW, van der Aa MN, Zwarthoff EC, et al. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative? *BJU Int* 2009 Jul;104(1):41-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/19500328>
75. Rouprêt M, Hupertan V, Yates DR, et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. *BJU Int* 2008 Jun;101(11):1448-53.  
<http://www.ncbi.nlm.nih.gov/pubmed/18325051>
76. Hong YM, Loughlin KR. Economic Impact of Tumor Markers in Bladder Cancer Surveillance. *Urology* 2008 Jan;71(1):131-5.  
<http://www.ncbi.nlm.nih.gov/pubmed/18242381>
77. Kurth KH, Schellhammer PF, Okajima E, et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. *Int J Urol* 1995 Jun;2(Suppl 2):8-22.  
<http://www.ncbi.nlm.nih.gov/pubmed/7553309>
78. Brausi M, Collette L, Kurth K, et al; EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence Rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. *Eur Urol* 2002 May;41(5):523-31.  
<http://www.ncbi.nlm.nih.gov/pubmed/12074794>
79. Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. *Eur Urol* 2010 May;57(5):843-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/19524354>
80. Van der Meijden A, Oosterlinck W, Brausi M, et al. Significance of bladder biopsies in Ta,T1 bladder tumours: a report of the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. *Eur Urol* 1999 Apr;35(4):267-71.  
<http://www.ncbi.nlm.nih.gov/pubmed/10419345>
81. Levi AW, Potter SR, Schoenberg MP et al. Clinical significance of denuded urothelium in bladder biopsy. *J Urol* 2001 Aug;166(2):457-60.  
<http://www.ncbi.nlm.nih.gov/pubmed/11458047>

82. Matzkin H, Soloway MS, Hardeman S. Transitional cell carcinoma of the prostate. *J Urol* 1991 Nov;146(5):1207-12.  
<http://www.ncbi.nlm.nih.gov/pubmed/1942262>
83. Mungan MU, Canda AE, Tuzel E, et al. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. *Eur Urol* 2005 Nov;48(5):760-3.  
<http://www.ncbi.nlm.nih.gov/pubmed/16005563>
84. Schmidbauer J, Witjes F, Schmeller N, et al; Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinatate fluorescence cystoscopy. *J Urol* 2004 Jan;171(1):135-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/14665861>
85. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinatate fluorescence cystoscopy: a new diagnostic tool for photodiagnosis of superficial bladder cancer -a multicenter study. *J Urol* 2003 Jul;170(1):226-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/12796694>
86. Hungerhuber E, Stepp H, Kriegmair M, et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. *Urology* 2007 Feb;69(2):260-4.  
<http://www.ncbi.nlm.nih.gov/pubmed/17320660>
87. Kausch I, Sommerauer M, Montorsi F, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. *Eur Urol* 2010 Apr;57(4):595-606.  
<http://www.ncbi.nlm.nih.gov/pubmed/20004052>
88. Draga RO, Grimbergen MC, Kok ET, et al. Photodynamic diagnosis (5 aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. *Eur Urol* 2010 Apr;57(4):655-60.  
<http://www.ncbi.nlm.nih.gov/pubmed/19819064>
89. Daniiltschenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. *J Urol* 2005 Dec;174(6):2129-33.  
<http://www.ncbi.nlm.nih.gov/pubmed/16280742>
90. Babjuk M, Soukup V, Petrik R, et al J. 5-aminolaevulinic acid -induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. *BJU Int* 2005 Oct;96(6):798-802.  
<http://www.ncbi.nlm.nih.gov/pubmed/16153204>
91. Denziger S, Burger M, Walter B, et al. Clinically relevant risk of reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid -induced fluorescence diagnosis: 8-years results of prospective randomized study. *Urology* 2007 Apr;69(4):675-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/17445650>
92. Schumacher MC, Holmäng S, Davidsson T, et al. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. *Eur Urol* 2010 Feb;57(2):293-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/19913351>
93. Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinatate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. *J Urol* 2010 Nov;184(5):1907-13.  
<http://www.ncbi.nlm.nih.gov/pubmed/20850152>
94. Witjes Ja, Redorta JP, Jacqmin D, et al. Hexaminolevulinatate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. *Eur Urol* 2010 Apr;57(4):607-14.  
<http://www.ncbi.nlm.nih.gov/pubmed/20116164>
95. Miladi M, Peyromaure M, Zerbib M, et al. The value of a second transurethral resection in evaluating patients with bladder tumours. *Eur Urol* 2003 Mar;43(3):241-5.  
<http://www.ncbi.nlm.nih.gov/pubmed/12600426>
96. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? *J Urol* 2001 Mar;165(3):808-10.  
<http://www.ncbi.nlm.nih.gov/pubmed/11176474>
97. Schips L, Augustin H, Zigeuner RE, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? *Urology* 2002 Feb;59(2):220-3.  
<http://www.ncbi.nlm.nih.gov/pubmed/11834389>

98. Grimm M-O, Steinhoff Ch, Simon X, et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. *J Urol* 2003 Aug;170(2 Pt 1):433-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/12853793>
99. Divrik RT, Yildirim Ü, Zorlu F, et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. *J Urol* 2006 May;175(5):1641-4.  
<http://www.ncbi.nlm.nih.gov/pubmed/16600720>
100. Jahnsen S, Wiklund F, Duchek M, et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder. *Scand J Urol Nephrol* 2005;39(3):206-10.  
<http://www.ncbi.nlm.nih.gov/pubmed/16127800>
101. Dalbagni G, Vora K, Kaag M, et al. Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer. *Eur Urol* 2009 Dec;56(6):903-10.  
<http://www.ncbi.nlm.nih.gov/pubmed/19632765>
102. Fritsche HM, Burger M, Svatek RS, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol* 2010 Feb;57(2):300-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/19766384>
103. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. *Eur Urol* 2010 Jan;57(1):60-70.  
<http://www.ncbi.nlm.nih.gov/pubmed/19740595>
104. Lopez-Beltran A, Bassi P, Pavone-Macaluso M, et al. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. *Eur Urol* 2004 Mar;45(3):257-66.  
<http://www.ncbi.nlm.nih.gov/pubmed/15036668>
105. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. *J Urol* 2000 Sep;164(3 Pt 1):680-4.  
<http://www.ncbi.nlm.nih.gov/pubmed/10954628>
106. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol* 2006 Mar;49(3):466-5.  
<http://www.ncbi.nlm.nih.gov/pubmed/16442208>
107. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. *J Urol* 2009 Nov;182(5):2195-203.  
<http://www.ncbi.nlm.nih.gov/pubmed/19758621>
108. Van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. *Eur Urol* 2010 Sep;58(3):433-41.  
<http://www.ncbi.nlm.nih.gov/pubmed/20646825>
109. Lamm DL. Carcinoma in situ. *Urol Clin North Am* 1992 Aug;19(3):499-508.  
<http://www.ncbi.nlm.nih.gov/pubmed/1636234>
110. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. *J Urol* 2000 Jan;163(1):68-72.  
<http://www.ncbi.nlm.nih.gov/pubmed/10604316>
111. Griffiths TRL, Charlton M, Neal DE, et al. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. *J Urol* 2002 Jun;167(6):2408-12.  
<http://www.ncbi.nlm.nih.gov/pubmed/11992047>
112. Takenaka A, Yamada Y, Miyake H, et al. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. *Int J Urol* 2008 Apr;15(4):309-13.  
<http://www.ncbi.nlm.nih.gov/pubmed/18380817>
113. Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. *J Urol* 2000 Sep;164( 3 Pt 1):685-89.  
<http://www.ncbi.nlm.nih.gov/pubmed/10953125>
114. Van Gils-Gielen RJ, Witjes WP, Caris CT, et al. Risk factors in carcinoma in situ of the urinary bladder. *Urology* 1995 Apr;45(4):581-6.  
<http://www.ncbi.nlm.nih.gov/pubmed/7716838>
115. Hudson MA, Herr HW. Carcinoma in situ of the bladder. *J Urol* 1995 Mar;153(3 Pt 1):564-72.  
<http://www.ncbi.nlm.nih.gov/pubmed/7861485>

116. Chade DC, Shariat SF, Godoy G, et al. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. *J Urol* 2010 Jul;184(1):74-80.  
<http://www.ncbi.nlm.nih.gov/pubmed/%2020546806>
117. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. *J Urol* 2004 Jun;171(6 Pt 1):2186-90.  
<http://www.ncbi.nlm.nih.gov/pubmed/15126782>
118. Berrum-Svennung I, Granfors T, Jahnsen S, et al. A Single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. *J Urol* 2008 Jan;179(1):101-5.  
<http://www.ncbi.nlm.nih.gov/pubmed/17997459>
119. Gudjonsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. *Eur Urol* 2009 Apr;55(4):773-80.  
<http://www.ncbi.nlm.nih.gov/pubmed/19153001>
120. Kaasinen E, Rintala E, Hellstrom P, et al; FinnBladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. *Eur Urol* 2002 Aug;42(2):167-74.  
<http://www.ncbi.nlm.nih.gov/pubmed/12160589>
121. Pan JS, Slocum HK, Rustum YM, et al. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. *J Urol* 1989 Dec;142(6):1589-93.  
<http://www.ncbi.nlm.nih.gov/pubmed/2511340>
122. Pode D, Alon Y, Horowitz AT, et al. The mechanism of human bladder tumor implantation in an in vitro model. *J Urol* 1986 Aug;136(2):482-6.  
<http://www.ncbi.nlm.nih.gov/pubmed/3525861>
123. Günther JH, Jurczok A, Wulf T, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). *Cancer Res* 1999 Jun;59(12):2834-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/10383142>
124. Böhle A, Jurczok A, Ardelt PU, et al. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. *J Urol* 2002 Jan;167(1):357-63.  
<http://www.ncbi.nlm.nih.gov/pubmed/11743356>
125. Hendricksen K, Witjes WP, Idema JG, et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. *Eur Urol* 2008 May;53(5):984-91.  
<http://www.ncbi.nlm.nih.gov/pubmed/18248876>
126. Böhle A, Leyh H, Frei C, et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. *Eur Urol* 2009 Sep;56(3):495-503.  
<http://www.ncbi.nlm.nih.gov/pubmed/19560257>
127. Oddens JR, van der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? *Eur Urol* 2004 Sep;46(3):336-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/15306104>
128. Engeler DS, Wyler S, Neyer M, et al. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases. *Scan J Urol Nephrol* 2008;42(6):522-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/18609290>
129. Solsona E, Iborra I, Ricos JV, et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. *J Urol* 1999 Apr;161(4):1120-3.  
<http://www.ncbi.nlm.nih.gov/pubmed/10081851>
130. Hinotsu S, Akaza H, Ohashi Y, et al. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. *Cancer* 1999 Nov;86(9):1818-26.  
<http://www.ncbi.nlm.nih.gov/pubmed/10547556>
131. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Part on Superficial Bladder Cancer. *J Urol* 1996 Dec;156(6):1934-40.  
<http://www.ncbi.nlm.nih.gov/pubmed/8911360>

132. Huncharek M, Geschwind J-F, Witherspoon B, et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. *J Clin Epidemiol* 2000 Jul;53(7):676-80.  
<http://www.ncbi.nlm.nih.gov/pubmed/10941943>
133. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. *Anticancer Res* 2001 Jan-Feb;21(1B):765-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/11299841>
134. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non muscle invasive bladder cancer: a systematic review of the published results of randomized clinical trials. *Eur Urol* 2008 Apr;53(4):709-19.  
<http://www.ncbi.nlm.nih.gov/pubmed/18207317>
135. Au JL, Baladament RA, Wientjes MG, et al; International Mitomycin C Consortium. International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. *J Natl Cancer Inst* 2001 Apr;93(8):597-604.  
<http://www.ncbi.nlm.nih.gov/pubmed/11309436>
136. Kuroda M, Niijima T, Kotake T, et al; 6th Trial of the Japanese Urological Cancer Research Group. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer -The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30 mg/40 ml, 40 mg/40 ml. *Eur Urol* 2004 May;45(5):600-5.  
<http://www.ncbi.nlm.nih.gov/pubmed/15082202>
137. Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. *BJU Int* 2001 Aug;88(3):209-16.  
<http://www.ncbi.nlm.nih.gov/pubmed/11488731>
138. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. *Urology* 2006 Jun;67(6):1216-23.  
<http://www.ncbi.nlm.nih.gov/pubmed/16765182>
139. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a metaanalysis of randomized trials. *BJU Int* 2004 Mar;93(4):485-90.  
<http://www.ncbi.nlm.nih.gov/pubmed/15008714>
140. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. *J Urol* 2003 Jan;169(1):90-5.  
<http://www.ncbi.nlm.nih.gov/pubmed/12478111>
141. Duchek M, Johansson R, Jahnson S, et al. Bacillus Calmette-Guérin Is superior to a combination of epirubicin and interferon- $\alpha$ 2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. a prospective, randomized, nordic study. *Eur Urol* 2010 Jan;57(1):25-31.  
<http://www.ncbi.nlm.nih.gov/pubmed/19819617>
142. Järvinen R, Kaasinen E, Sankila A, et al. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. *Eur Urol* 2009 Aug;56(2):260-5.  
<http://www.ncbi.nlm.nih.gov/pubmed/19395154>
143. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. *Eur Urol* 2010 May;57(5):766-73.  
<http://www.ncbi.nlm.nih.gov/pubmed/20034729>
144. Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. *Eur Urol* 2009 Aug;56(2):247-56.  
<http://www.ncbi.nlm.nih.gov/pubmed/19409692>
145. Böhle A, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. *Urology* 2004 Apr;63(4):682-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/15072879>

146. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. *J Urol* 2002 Nov;168(5):1964-70.  
<http://www.ncbi.nlm.nih.gov/pubmed/12394686>
147. Huncharek, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder. *Am J Clin Oncol* 2003 Aug;26(4):402-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/12902895>
148. Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. *Am J Clin Oncol* 2004 Oct;27(5):522-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/15596924>
149. Morales, A, Eiding D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. *J Urol* 1976 Aug;116(2):180-3.  
<http://www.ncbi.nlm.nih.gov/pubmed/820877>
150. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. *J Urol* 2000 Apr;163(4):1124-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/10737480>
151. Zlotta AR, van Vooren JP, Huygen K, et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? *Eur Urol* 2000 Apr;37(4):470-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/10765079>
152. Martinez-Pineiro JA, Flores N, Isorna S, et al; for CUETO (Club Urológico Español De Tratamiento Oncológico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. *BJU Int* 2002 May;89(7):671-80.  
<http://www.ncbi.nlm.nih.gov/pubmed/11966623>
153. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al; Club Urológico Español De Tratamiento Oncológico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumours than the standard dose? Results of a prospective randomized trial. *J Urol* 2005 Oct;174(4 Pt 1):1242-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/16145378>
154. Ojea A, Nogueira JL, Solsona E, et al; CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C. *Eur Urol* 2007 Nov;52(5):1398-406.  
<http://www.ncbi.nlm.nih.gov/pubmed/17485161>
155. Van der Meijden AP, Sylvester RJ, Oosterlinck W, et al; EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta, T1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. *Eur Urol* 2003 Oct;44(4):429-34.  
<http://www.ncbi.nlm.nih.gov/pubmed/14499676>
156. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. *J Urol* 1992 Mar;147(3):596-600.  
<http://www.ncbi.nlm.nih.gov/pubmed/1538436>
157. Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. *Eur Urol Suppl* 2008 Oct;7(10):667-74.
158. Rodríguez F, Palou J, Martínez R, et al. Practical guideline for the management of adverse events associated with BCG installations. *Arch Esp Urol*. 2008 Jun;61(5):591-6. [Article in Spanish]  
<http://www.ncbi.nlm.nih.gov/pubmed/18709813>
159. Jakse G, Hall R, Bono A, et al and members of the EORTC GU Group. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. *Eur Urol* 2001 Aug;40(2):144-50.  
<http://www.ncbi.nlm.nih.gov/pubmed/11528191>
160. Gofrit ON, Pode D, Pizov G, et al. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guérin immunotherapy. *Urol Oncol* 2009 May-Jun;27(3):258-62.  
<http://www.ncbi.nlm.nih.gov/pubmed/18440839>

161. Sylvester RJ, van der Meijden APM, Witjes JA, et al. Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. *J Urol* 2005 Jul;174(1):86-92.  
<http://www.ncbi.nlm.nih.gov/pubmed/15947584>
162. Kaasinen E, Wijkstrom H, Malmstrom PU, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. *Eur Urol* 2003 Jun;43(6):637-45.  
<http://www.ncbi.nlm.nih.gov/pubmed/12767365>
163. Solsona E, Iborra I, Ricos JV, et al. Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. *J Urol* 1996 Mar;155(3):895-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/8583601>
164. Kurth KH, Schellhammer PF, Okajima E, et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. *Int J Urol* 1995 Jun;2 Suppl 2:8-22.  
<http://www.ncbi.nlm.nih.gov/pubmed/7553309>
165. Palou J, Baniel J, Klotz L, et al. Urothelial carcinoma of the prostate. *Urology* 2007 Jan;69(1 Suppl):50-61.  
<http://www.ncbi.nlm.nih.gov/pubmed/17280908>
166. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumours. *J Urol* 2003 May;169(5):1706-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/12686813>
167. Lerner SP, Tangen CM, Sucharew H, et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non muscle invasive bladder cancer. *Urol Oncol* 2009 Mar-Apr;27(2):155-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/18367117>
168. Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. *J Urol* 2000 Sep;164(3 Pt 1):685-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/10953125>
169. Gallagher BL, Joudi FN, Maymi JL, et al. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. *Urology* 2008 Feb;71(2):297-301.  
<http://www.ncbi.nlm.nih.gov/pubmed/18308107>
170. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. *J Clin Oncol* 2006 Jun;24(18):2729-34.  
<http://www.ncbi.nlm.nih.gov/pubmed/16782913>
171. Mohanty NK, Nayak RL, Vasudeva P, et al. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. *Urol Oncol* 2008 Nov-Dec;26(6):616-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/18367121>
172. Barlow L, McKiernan J, Sawczuk I, et al. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacilli Calmette-Guerin therapy. *BJU Int* 2009 Oct;104(8):1098-102.  
<http://www.ncbi.nlm.nih.gov/pubmed/19389012>
173. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. *J Urol* 2000 Mar;163(3):761-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/10687972>
174. Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. *J Urol* 2009 Oct; 182(4):1313-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/19683278>
175. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. *Urol Oncol* 2006 Jul-Aug;24(4):344-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/16818189>
176. Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. *Cancer* 2010 Apr;116(8):1893-900.  
<http://www.ncbi.nlm.nih.gov/pubmed/20162706>



177. Yates DR, Rouprêt M. Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options. *BJU International* 2010 Jul;106(2):162-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/20201829>
178. Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. *Can Urol Assoc J* 2009 Dec;3(6 Suppl 4):S199-205.  
<http://www.ncbi.nlm.nih.gov/pubmed/20019985>
179. Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. *J Urol* 2007 Apr;177(4):1283-6.  
<http://www.ncbi.nlm.nih.gov/pubmed/17382713>
180. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol* 2001 Feb;19(3):666-75.  
<http://www.ncbi.nlm.nih.gov/pubmed/11157016>
181. Hautmann RE, Gschwend JE, de Petriconi RC, et al. Cystectomy for transitional cell carcinoma of the bladder: results of surgery only series in the neobladder era. *J Urol* 2006 Aug;176(2):486-92.  
<http://www.ncbi.nlm.nih.gov/pubmed/16813874>
182. Ghoneim MA, Abdel-Latif M, El-Mekresh M, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 year later. *J Urol* 2008 Jul;180(1):121-7.  
<http://www.ncbi.nlm.nih.gov/pubmed/18485392>
183. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. *J Clin Oncol* 2003 Feb;21(4):690-6.  
<http://www.ncbi.nlm.nih.gov/pubmed/12586807>
184. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium. *J Urol* 2006 Dec;176(6 Pt 1):2414-22.  
<http://www.ncbi.nlm.nih.gov/pubmed/17085118>
185. Shariat SF, Palapattu GS, Amiel GE, et al. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. *Urology* 2006 Sep;68(3):538-42.  
<http://www.ncbi.nlm.nih.gov/pubmed/16979748>
186. Oge O, Erdem E, Atsu N, et al. Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumour. *Eur Urol* 2000 Mar;37(3):271-4.  
<http://www.ncbi.nlm.nih.gov/pubmed/10720851>
187. Holmäng S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumours: relationship to grade, immunohistochemical expression of tumour markers, mitotic frequency and DNA ploidy. *J Urol* 2001 Apr;165(4):1124-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/11257652>
188. Fujii Y, Kawakami S, Koga F, et al. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. *BJU Int* 2003 Oct;92(6):559-62.  
<http://www.ncbi.nlm.nih.gov/pubmed/14511033>
189. Leblanc B, Duclos AJ, Bénard F, et al. Long-term follow-up of initial Ta grade 1 transitional cell carcinoma of the bladder. *J Urol* 1999 Dec;162(6):1946-50.  
<http://www.ncbi.nlm.nih.gov/pubmed/10569544>
190. Zieger K, Wolf H, Olsen PR, et al. Long-term follow-up of non-invasive bladder tumours (stage Ta): recurrence and progression. *BJU Int* 2000 May;85(7):824-8.  
<http://www.ncbi.nlm.nih.gov/pubmed/10792160>
191. Borhan A, Reeder JE, O'Connell MJ, et al. Grade progression and regression in recurrent urothelial cancer. *J Urol* 2003 Jun;169(6):2106-9.  
<http://www.ncbi.nlm.nih.gov/pubmed/12771728>
192. Soloway M, Bruck DS, Kim SS. Expectant management of small recurrent, non-invasive papillary bladder tumours. *J Urol* 2003 Aug;170(2 Pt 1):438-41.  
<http://www.ncbi.nlm.nih.gov/pubmed/12853794>
193. Gofrit ON, Pode D, Lazar A, et al. Watchful waiting policy in recurrent Ta G1 bladder tumours. *Eur Urol* 2006 Feb;49(2):303-6.  
<http://www.ncbi.nlm.nih.gov/pubmed/16413659>
194. Herr HW, Donat SM, Reuter VE. Management of Low Grade Papillary Bladder Tumors. *J Urol* 2007 Oct;178(4 Pt 1):2201-5.  
<http://www.ncbi.nlm.nih.gov/pubmed/17698090>
195. Pruthi RS, Baldwin N, Bhalani V, et al. Conservative Management of Low Risk Superficial Bladder Tumors. *J Urol* 2008 Jan;179(1):87-90.  
<http://www.ncbi.nlm.nih.gov/pubmed/17997444>

196. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002 Apr;167(4):1634-7. <http://www.ncbi.nlm.nih.gov/pubmed/11912378>
197. Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 2005 Apr;173(4):1008-11. <http://www.ncbi.nlm.nih.gov/pubmed/15758711>

## 11. ABBREVIATIONS USED IN THE TEXT

*This list is not comprehensive for the most common abbreviations.*

5-ALA	5-aminolaevulinic acid
ASR	age standardised incidence rate
BCG	bacillus Calmette-Guérin
BTA	bladder tumour antigen
CIS	carcinoma <i>in situ</i>
CT	computed tomography
CUETO	Club Urológico Español de Tratamiento Oncológico (Spanish Oncology Group)
EAU	European Association of Urology
EORTC	European Organization for Research and Treatment of Cancer
EORTC-GU	EORTC Genitourinary group
FISH	fluorescence <i>in situ</i> hybridisation
GR	grade of recommendation
HAL	hexaminolaevulinic acid
ISUP	International Society of Urological Pathology
IVU	intravenous urography
LE	level of evidence
MMC	mitomycin C
NMIBC	non-muscle-invasive bladder cancer
NVP	negative predictive value
PDD	photodynamic diagnosis
PUNLMP	papillary urothelial neoplasms of low malignant potential
RCT	randomised controlled trial
TCC	transitional cell carcinoma
TNM	tumour, node, metastasis
TUR	transurethral resection
UICC	Union International Contre le Cancer
US	ultrasonography
WHO	World Health Organization

### **Conflict of interest**

All members of the Non-Muscle-Invasive Bladder Cancer guidelines working group have provided disclosure statements of all the relationships that they have and which might be perceived as a potential source of conflict of interest. This information is kept on file in the EAU Central Office database. This guidelines document was developed with the financial support of the EAU. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

